Head-to-head evidence
efsubaglutide alfa vs ZT002
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
efsubaglutide alfa
Developed by Shanghai Yinnuo Pharmaceutical Technology
NCT06732960 · Phase 2 · completed
The study was randomized, double-blind, and placebo-controlled, but each dose cohort was small, with approximately 10 participants per cohort and a 8:2 active-to-placebo allocation. Because the registry provides no primary endpoint results, it is not possible to determine whether the weight-loss comparison was met.
Next expected readout: November 2026 · NCT07163650 (registry estimate)
ZT002
Developed by Beijing QL Biopharmaceutical
NCT07020884 · Phase 2 · completed
This randomized, double-blind, placebo-controlled Phase 2 trial (n=303) in adults with overweight or obesity found that ZT002 produced significantly greater weight loss than placebo at 24 weeks across all doses tested, up to 14.4% versus 2.4% with placebo (p<0.0001).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT07443059 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: efsubaglutide alfa's landscape · ZT002's landscape